Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer drug tame graft-versus-host disease when steroids fail?

NCT ID NCT05621733

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study follows about 140 people in Korea who have steroid-refractory graft-versus-host disease (GvHD) — a serious complication after a stem cell transplant where donor immune cells attack the recipient's body. Researchers are tracking how well the drug ruxolitinib (Jakavi) works and what side effects occur when it is used in real-world medical practice. The goal is to see if the drug's benefits seen in clinical trials hold up outside of a controlled research setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ruxolitinib (Jakavi), a drug that calms an overactive immune response
What this could lead to
If the drug performs well in everyday practice, it could confirm ruxolitinib as a reliable option for controlling severe GvHD when steroids fail.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient differences and real-world variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT VERSUS HOST DISEASE

Contacts and locations

Locations

  • Novartis Investigative Site

    Daegu, Dalseo gu, 42602, South Korea

  • Novartis Investigative Site

    Wŏnju, Gangwon-do, 26426, South Korea

  • Novartis Investigative Site

    Uijeongbu-si, Gyeonggi-do, 11759, South Korea

  • Novartis Investigative Site

    Jinju, Gyeongsangnam-do, 52727, South Korea

  • Novartis Investigative Site

    Gyeonggi-do, Korea, 10408, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 02841, South Korea

  • Novartis Investigative Site

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    Busan, 48108, South Korea

  • Novartis Investigative Site

    Busan, 49241, South Korea

  • Novartis Investigative Site

    Busan, 602-030, South Korea

  • Novartis Investigative Site

    Jeollanam, 519763, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    Seoul, 06591, South Korea

  • Novartis Investigative Site

    Taegu, 41944, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.